- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
16
High return on equity, past performance and sound balance sheet.
16 companies
Medpace Holdings
Market Cap: US$13.4b
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
MEDP
US$475.51
7D
2.6%
1Y
33.8%
Exelixis
Market Cap: US$10.1b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$37.42
7D
-3.1%
1Y
43.8%
Catalyst Pharmaceuticals
Market Cap: US$2.5b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$20.59
7D
-2.3%
1Y
1.7%
Waters
Market Cap: US$18.0b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$301.80
7D
-0.1%
1Y
-12.9%
ACADIA Pharmaceuticals
Market Cap: US$4.4b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$25.99
7D
1.0%
1Y
56.8%
Harmony Biosciences Holdings
Market Cap: US$2.1b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$36.89
7D
-2.6%
1Y
2.5%
Incyte
Market Cap: US$16.5b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$84.61
7D
-0.5%
1Y
28.9%
CytomX Therapeutics
Market Cap: US$336.4m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$2.04
7D
-3.8%
1Y
72.9%
CureVac
Market Cap: US$1.2b
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
CVAC
US$5.37
7D
-1.3%
1Y
71.0%
BioStem Technologies
Market Cap: US$118.8m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$7.10
7D
22.4%
1Y
-35.6%
Puma Biotechnology
Market Cap: US$253.9m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$5.04
7D
-4.0%
1Y
101.6%
ADMA Biologics
Market Cap: US$4.1b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$17.26
7D
-3.0%
1Y
-0.3%
Corcept Therapeutics
Market Cap: US$7.3b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$69.72
7D
-0.9%
1Y
97.5%
Niagen Bioscience
Market Cap: US$791.2m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$9.90
7D
-0.8%
1Y
187.0%
Champions Oncology
Market Cap: US$93.8m
A technology-enabled research company, provides technology solutions for drug discovery and development in the United States.
CSBR
US$6.80
7D
-10.9%
1Y
61.1%
Earth Science Tech
Market Cap: US$58.9m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.20
7D
-4.8%
1Y
-2.4%